<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823459</url>
  </required_header>
  <id_info>
    <org_study_id>08109</org_study_id>
    <secondary_id>NCI-2011-01701</secondary_id>
    <secondary_id>08109</secondary_id>
    <nct_id>NCT00823459</nct_id>
    <nct_alias>NCT00831324</nct_alias>
  </id_info>
  <brief_title>Everolimus in Treating Patients With Recurrent Low-Grade Glioma</brief_title>
  <official_title>Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susan Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      This phase II trial studies how well everolimus works in treating patients with recurrent
      low-grade glioma. Everolimus may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth or by blocking blood flow to the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      1. To determine progression-free survival at 6 months associated with use of RAD001
      (everolimus) in patients initially diagnosed with low-grade glioma who undergo biopsy or
      subtotal resection at the time of recurrence with pathologic evidence of recurrent low-grade
      glioma (LGG).

      SECONDARY OBJECTIVES:

        1. To further delineate the safety profile of RAD001 in patients with recurrent LGG.

        2. To assess overall survival (OS) in patients treated with RAD001.

        3. To assess the objective response rate (ORR) in patients treated with RAD001.

        4. To assess the correlation of protein kinase B (PKB)/Akt and phosphatase and tensin
           homolog (PTEN) expression with response, progression status by 6 months, and OS in
           patients treated with RAD001.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2009</start_date>
  <completion_date type="Actual">November 13, 2017</completion_date>
  <primary_completion_date type="Actual">June 12, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival at 6 Months.</measure>
    <time_frame>At 6 months after treatment start</time_frame>
    <description>Number of patients alive without progressive disease at 6 months. Assessment of progression was defined by RANO as a 25% increase in the sum of all the products of measurable lesions, clear worsening of any evaluable disease or any new lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RAD001 Safety Profile in Patients With Recurrent LLG</measure>
    <time_frame>13 months</time_frame>
    <description>Grade 4-5 treatment related adverse events as defined by CTCAE 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in Patients Treated With RAD001.</measure>
    <time_frame>12 months</time_frame>
    <description>Objective response is defined as complete or partial response as defined by RANO criteria as determined by MRI and steroid requirement. Complete response was defined by disappearance of all measurable disease with minimal or no steroids; a partial response was defined as 50% in sum of all products in perpendicular diameters of all measurable lesions with no new lesions on stable or decreasing steroids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Patients Treated With RAD001.</measure>
    <time_frame>Time from registration till death, an average of 5 years</time_frame>
    <description>Number of years from the day the patient started treatment until the date of death, an average of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Correlation of Activation of the PI3K/mTOR Pathway With Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Survival of patients with p-S6 staining of &gt;19% (activated pathway)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Adult Diffuse Astrocytoma</condition>
  <condition>Adult Mixed Glioma</condition>
  <condition>Adult Oligodendroglioma</condition>
  <condition>Adult Subependymal Giant Cell Astrocytoma</condition>
  <condition>Recurrent Adult Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>Single-Arm Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm study with patients receiving Everolimus orally once daily dosing of 10 mg continuously from Day 1 of study until progression of disease or unacceptable toxicity. In addition archival tissue will be analysed for markers of P13K/mTOR pathway activation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Single-Arm Everolimus</arm_group_label>
    <other_name>42-O-(2-Hydroxy)ethyl Rapamycin</other_name>
    <other_name>Afinitor</other_name>
    <other_name>Certican</other_name>
    <other_name>RAD 001</other_name>
    <other_name>RAD001</other_name>
    <other_name>Votubia</other_name>
    <other_name>Zortress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Archival Tissue Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Single-Arm Everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a Karnofsky performance status of &gt;= 60

          -  Patients must have a life expectancy &gt; 8 weeks

          -  All patients must sign an informed consent document indicating that they are aware of
             the investigational nature of this study

          -  Patients must sign an authorization for the release of their protected health
             information

          -  Patients must have a magnetic resonance imaging (MRI) scan performed within 14 days
             prior to initial protocol treatment

          -  Patients must be registered in the University of California at San Francisco (UCSF)
             Neuro-Oncology database prior to treatment with study drug

          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L

          -  Platelets &gt;= 100 x 10^9/L

          -  Hemoglobin (Hb) &gt; 9 g/dL

          -  Serum bilirubin =&lt; 1.5 x upper limit of normal (ULN)

          -  International normalized ratio (INR) &lt; 1.5 (anticoagulation is allowed if target INR
             =&lt; 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight [LMW]
             heparin for &gt; 2 weeks at the time of registration)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 x ULN

          -  Serum creatinine =&lt; 1.5 x ULN

          -  Fasting serum cholesterol =&lt; 300 mg/dL OR =&lt; 7.75 mmol/L AND fasting triglycerides =&lt;
             2.5 x ULN; NOTE: In case one or both of these thresholds are exceeded, the patient can
             only be included after initiation of appropriate lipid lowering medication

          -  Patients must have histologically proven intracranial low-grade glioma at initial
             diagnosis; low-grade gliomas include: astrocytoma, oligodendroglioma and mixed
             oligoastrocytoma; pilocytic astrocytomas are excluded

          -  Patients must have unequivocal evidence for tumor recurrence or progression by
             histology as determined by review of pathology by an attending neuro-pathologist at
             UCSF

          -  If most recent histology shows progression to high grade glioma, patients must have
             had prior radiotherapy in order to be eligible

          -  Paraffin-embedded sections of tissue acquired from surgery at the time of suspected
             recurrence must be available for analysis

          -  Patients must have evidence for tumor recurrence or progression by MRI as determined
             by radiographic review of images by an attending neuro-oncologist or neuro-radiologist
             at UCSF

          -  If the steroid dose is increased between the date of the MRI and registration on the
             trial, a new baseline MRI is required; this MRI must be performed after &gt;= 5 days on a
             stable dose of steroids

          -  An MRI must be used throughout the period of protocol treatment for tumor measurement

          -  Patients must have evaluable disease

          -  Patients may have had treatment (including radiotherapy) for any number of relapses
             prior to this recurrence

          -  Patients must be at least 4 weeks from the completion of any radiation therapy

          -  Patients must be less than 4 months from the surgical procedure for this recurrence

          -  Patients must have recovered from the toxic effects of prior therapy:

               -  4 weeks from any investigational agent

               -  4 weeks from prior cytotoxic therapy (except 6 weeks from nitrosoureas, 3 weeks
                  from procarbazine, 3 weeks from vincristine)

               -  3 weeks for non-cytotoxic or biologic agents e.g., interferon, tamoxifen,
                  thalidomide, cis-retinoic acid, tarceva, etc; note a 3-week washout is required
                  for prior treatment with bevacizumab

        Exclusion Criteria:

          -  Patients who have not recovered from the side effects of a major surgery or
             significant traumatic injury or patients that may require major surgery during the
             course of the study

          -  Patients receiving chronic, systemic treatment with corticosteroids or another
             immunosuppressive agent; topical or inhaled corticosteroids, and treatment with low
             dose Decadron (=&lt; 3 mg daily) are allowed

          -  Other than surgery, patients may not have therapy for this recurrence (including
             radiation); supportive care such as steroids or anti-epileptics does not constitute
             treatment of recurrence

          -  Patients must not have any significant medical illnesses that in the investigator?s
             opinion cannot be adequately controlled with appropriate therapy or would compromise
             the patient?s ability to tolerate this therapy

          -  Patients with a history of any other cancer (except for adequately treated carcinoma
             of the cervix or basal or squamous cell carcinomas of the skin), unless in complete
             remission and off of all therapy for that disease for a minimum of 3 years are
             ineligible

          -  Patients should not receive immunization with attenuated live vaccines within one week
             of study entry or during study period; close contact with those who have received
             attenuated live vaccines should be avoided during treatment with everolimus; examples
             of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio,
             Bacillus Calmette-Gu?rin (BCG), yellow fever, varicella and TY21a typhoid vaccines

          -  Uncontrolled brain or all leptomeningeal metastases, including patients who continue
             to require glucocorticoids for brain or leptomeningeal metastases

          -  Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study such as:

               -  Symptomatic congestive heart failure of New York heart Association Class III or
                  IV

               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial
                  infarction within 6 months of start of study drug, serious uncontrolled cardiac
                  arrhythmia or any other clinically significant cardiac disease

               -  Severely impaired lung function

               -  Uncontrolled diabetes as defined by fasting serum glucose &gt; 1.5 x ULN (Note:
                  Optimal glycemic control should be achieved before starting trial therapy)

               -  Active (acute or chronic) or uncontrolled severe infections

               -  Liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C)

          -  A Hepatitis B/C blood test must be done at screening for all patients; patients who
             test positive for Hepatitis C antibodies and the Hepatitis B antigen are ineligible

          -  A known history of human immunodeficiency virus (HIV) seropositivity

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled
             nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)

          -  Impaired lung function: O2 saturation 88% or less at rest on room air by pulse
             oximetry; if O2 saturation is =&lt; 88% at rest, further pulmonary function tests (PFTs)
             should be ordered to confirm normal pulmonary function and eligibility

          -  Patients with an active, bleeding diathesis

          -  Female patients who are pregnant or breast feeding, or adults of reproductive
             potential who are not using effective birth control methods; adequate contraception
             must be used throughout the trial and for 8 weeks after the last dose of study drug,
             by both sexes (women of childbearing potential [WOCBP] must have a negative urine or
             serum pregnancy test within 7 days prior to administration of RAD001)

          -  Male patient whose sexual partner(s) are WOCBP who are not willing to use adequate
             contraception, during the study and for 8 weeks after the end of treatment

          -  Patients who have received prior treatment with an mammalian target of rapamycin
             (mTOR) inhibitor (e.g., sirolimus, temsirolimus, everolimus)

          -  Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins
             (e.g., sirolimus, temsirolimus) or to its excipients

          -  History of noncompliance to medical regimens

          -  Patients unwilling to or unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <results_first_submitted>May 24, 2017</results_first_submitted>
  <results_first_submitted_qc>April 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2019</results_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Susan Chang</investigator_full_name>
    <investigator_title>MD, Professor in Residence</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 15, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT00823459/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Daily Intervention With RAD001</title>
          <description>Single arm study: RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population is the same as the assigned participant flow.</population>
      <group_list>
        <group group_id="B1">
          <title>Daily Intervention With RAD001</title>
          <description>RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival at 6 Months.</title>
        <description>Number of patients alive without progressive disease at 6 months. Assessment of progression was defined by RANO as a 25% increase in the sum of all the products of measurable lesions, clear worsening of any evaluable disease or any new lesion</description>
        <time_frame>At 6 months after treatment start</time_frame>
        <population>All patients treated with study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Intervention With RAD001</title>
            <description>RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.
RAD001: RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival at 6 Months.</title>
          <description>Number of patients alive without progressive disease at 6 months. Assessment of progression was defined by RANO as a 25% increase in the sum of all the products of measurable lesions, clear worsening of any evaluable disease or any new lesion</description>
          <population>All patients treated with study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III/IV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RAD001 Safety Profile in Patients With Recurrent LLG</title>
        <description>Grade 4-5 treatment related adverse events as defined by CTCAE 3.0</description>
        <time_frame>13 months</time_frame>
        <population>All patients treated from the time of registration until discontinuation of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Intervention With RAD001</title>
            <description>RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>RAD001 Safety Profile in Patients With Recurrent LLG</title>
          <description>Grade 4-5 treatment related adverse events as defined by CTCAE 3.0</description>
          <population>All patients treated from the time of registration until discontinuation of study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) in Patients Treated With RAD001.</title>
        <description>Objective response is defined as complete or partial response as defined by RANO criteria as determined by MRI and steroid requirement. Complete response was defined by disappearance of all measurable disease with minimal or no steroids; a partial response was defined as 50% in sum of all products in perpendicular diameters of all measurable lesions with no new lesions on stable or decreasing steroids.</description>
        <time_frame>12 months</time_frame>
        <population>All patients who were treated with study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Intervention With RAD001</title>
            <description>RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.
RAD001: RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) in Patients Treated With RAD001.</title>
          <description>Objective response is defined as complete or partial response as defined by RANO criteria as determined by MRI and steroid requirement. Complete response was defined by disappearance of all measurable disease with minimal or no steroids; a partial response was defined as 50% in sum of all products in perpendicular diameters of all measurable lesions with no new lesions on stable or decreasing steroids.</description>
          <population>All patients who were treated with study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in Patients Treated With RAD001.</title>
        <description>Number of years from the day the patient started treatment until the date of death, an average of 5 years.</description>
        <time_frame>Time from registration till death, an average of 5 years</time_frame>
        <population>All patients in study</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Intervention With RAD001</title>
            <description>RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in Patients Treated With RAD001.</title>
          <description>Number of years from the day the patient started treatment until the date of death, an average of 5 years.</description>
          <population>All patients in study</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="4" upper_limit="NA">Upper limit of confidence interval not reached due to insufficient number of patients with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Correlation of Activation of the PI3K/mTOR Pathway With Survival</title>
        <description>Survival of patients with p-S6 staining of &gt;19% (activated pathway)</description>
        <time_frame>5 years</time_frame>
        <population>Patients for which the molecular marker PI3K pathway activation was available</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Intervention With RAD001</title>
            <description>RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.
RAD001: RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Correlation of Activation of the PI3K/mTOR Pathway With Survival</title>
          <description>Survival of patients with p-S6 staining of &gt;19% (activated pathway)</description>
          <population>Patients for which the molecular marker PI3K pathway activation was available</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="3.4" upper_limit="NA">Upper bound not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of study start with first day of study dosing until patient is removed from protocol treatment up to 12 months of therapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Daily Intervention With RAD001</title>
          <description>RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Infection with normal ANC or Grade 1 or 2 neutrophils
- Meninges (meningitis)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Seizure</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain-Head/headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary</sub_title>
                <description>Malilgnancy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>Pneumonitis/pulmonary infiltrates</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <description>ANC</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="14" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>mucositis/stomatitis</sub_title>
                <description>Oral cavity</description>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>mucosititis/stomatitis</sub_title>
                <description>Anus</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Abdominal NOS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>In absence of neutropenia,where neutropenia is defined as ANC &lt; 1.0 x 10e9/L</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>with Grade III or IV neurtophils (ANC &lt; 1.0x 10e9/L) - Lung</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (30)">Infection</sub_title>
                <description>With normal ANC or Grade 1 or 2 neurtrophils - meninges (meningitis)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased ALT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>hypertriglyceridemia</sub_title>
                <description>Triglyceride, serum-high</description>
                <counts group_id="E1" events="16" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypophosephatemia</sub_title>
                <description>Phosphate, serum - low</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypercholesteremia</sub_title>
                <description>Cholesterol, serum-high</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Glucose, Serum - high</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>Potassium, serum - high</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <description>Sodium, serum - high</description>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <description>Serum glutamic pyruvic transaminase - serum high</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Back</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <description>Generalized</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft Tissue</sub_title>
                <description>Other</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>ataxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dizzness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>neuropathy</sub_title>
                <description>Motor</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>mood alteration</sub_title>
                <description>Agitation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Mood Alteration</sub_title>
                <description>Depression</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <description>Sensory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Speech Impairment</sub_title>
                <description>dysphasia or aphasia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Fainting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary</sub_title>
                <description>Renal/Genitourinary malignancy, Urinary frequency/urgency</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Chest/Thorax</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Shortness of breath</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>Pulmonary Infiltrates</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>desquamation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>acne/acneiform</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Chang, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 353-2966</phone>
      <email>jessica.carlson@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

